Product Description
IGF-1 LR3 (Long Arg3 IGF-1) is a modified analog of Insulin-like Growth Factor-1 designed with an extended half-life and reduced binding affinity to IGF-binding proteins compared to native IGF-1. Structural modifications enhance its stability and prolong its activity in experimental settings. IGF-1 LR3 has been studied for its involvement in cellular growth signaling pathways and metabolic regulation mechanisms.
Effects
IGF-1 LR3 has been investigated for its role in cellular proliferation signaling, anabolic pathway activation, and glucose metabolism modulation. Due to its extended activity profile, it demonstrates sustained interaction with IGF-1 receptors in research environments. Observational data relate to growth-factor-mediated signaling and tissue response mechanisms.
Side Effects
Reported side effects may include injection-site discomfort, transient fatigue, headache, or fluctuations in blood glucose levels. Individual response may vary depending on sensitivity and preparation conditions.
Stacking
IGF-1 LR3 is typically referenced within structured research protocols focused on growth-factor pathways. Combination with other endocrine-active compounds should be evaluated carefully to ensure pathway compatibility and controlled application.
EN 
UA